- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 620
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
- Drug · Procedure · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 334
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Interventions
- Team-Based Connected Health (TCH)
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Lower Back Pain, Lumbar Radiculopathy
- Interventions
- Virtual reality, Intravenous sedation, Standard care
- Device · Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Prednisone, Topical mometasone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
- Interventions
- Emapalumab, Fludarabine and Dexamethasone, Allogeneic hematopoietic stem cell transplant (allo-HCT)
- Drug · Procedure
- Lead sponsor
- Joseph Oved
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- San Francisco, California • Atlanta, Georgia • Basking Ridge, New Jersey + 9 more
- Conditions
- Asthma
- Interventions
- Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
- Conditions
- Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Interventions
- Vitamin D (VitD), Placebo, Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care)
- Dietary Supplement · Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- Enzalutamide, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Dysphagia
- Interventions
- Dilation, Triamcinolone Injection, Esophagogastroduodenoscopy (EGD)
- Procedure · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 1,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
- Conditions
- T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 1,895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 191
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Terence Friedlander, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- San Francisco, California • Portland, Oregon
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 1 Year
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
- Conditions
- Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
- Interventions
- Fecal Microbiota Transplantation (FMT)
- Biological
- Lead sponsor
- Leland Metheny
- Other
- Eligibility
- 19 Years to 74 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab, Dexamethasone, Ixazomib
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Carpal Tunnel Syndrome
- Interventions
- Fat Injection, Steroid Injection
- Other · Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rhabdomyolysis
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Nivolumab, Etoposide, Prednisolone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Headache, Occipital Nerve Block
- Interventions
- Bupivacaine, Lidocaine, Dexamethasone, Normal saline, Greater/lesser occipital nerve blocks
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Lymphocytic Leukemia
- Interventions
- aminopterin, L-asparaginase, cyclophosphamide, cytarabine, daunomycin, dexamethasone, 6-mercaptopurine, methotrexate, 6-thioguanine, vincristine, Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone), Leucovorin
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 2
- States / cities
- Neptune City, New Jersey • New Brunswick, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
- Drug
- Lead sponsor
- Amany Keruakous, MD, MS.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more